Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CBP501 to enhance anti-cancer cytotoxic activity, when combined with selected chemotherapeutic drugs
Subscribe to our email newsletter
CanBas and Takeda, along with Takeda Oncology, have initiated the phase-II clinical trials of CBP501, for the treatment of patients with non-small cell lung cancer (NSCLC).
Data from a previous phase-I study indicated that CBP501 may enhance anti-cancer cytotoxic activity, when combined with selected chemotherapeutic drugs.
CanBas and Takeda signed a collaboration agreement in March 2007, for the development of investigational compounds to treat patients with cancer (including CBP501 and its backup compounds discovered by CanBas).
Under the terms of the agreement, the worldwide exclusive rights for development, manufacturing and marketing have been granted to Takeda. While in the US, the development and promotion are jointly conducted by both the companies.
Takumi Kawabe, President and CEO of CanBas, said: We are excited to see CBP501 moving to Phase II trials in non-small cell lung cancer. This is the second Phase II trial for CBP501, and we look forward to advancing both indications toward an eventual marketing authorization.